$5.35
Today
as of Jul 22, 16:25 ET
Last 30 days
Recent Press Releases & News
Vanda Reports Positive Opinion for Imsidolimab Orphan Drug Label
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
Overview
52-week range
$4.14
$9.94
21% of range
Avg surprise (last 3)
-27.0%
Avg reaction (last 2)
+0.5%
100% positive
Latest IV / EM
61%
EM ±14.0% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-0.82 | $-0.53 | -54.7% | -64.0% | +0.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.38 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jun/2025 | $-0.46 | $-0.34 | -35.3% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-0.50 | $-0.55 | +9.1% | — | +0.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.09 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.08 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.07 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | — | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.03 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | OTHER | -$0.50 | -$0.46 | -8.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $52M | — | $56M | $53M | $50M | — | $48M | $50M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-50M | — | $-31M | $-39M | $-41M | — | $-11M | $-10M |
| Net income | $-49M | — | $-23M | $-27M | $-29M | — | $-5M | $-5M |
| EPS (diluted) | $-0.82 | — | $-0.38 | $-0.46 | $-0.50 | — | $-0.09 | $-0.08 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $54M | $85M | $70M | $81M | $112M | $102M | $100M | $103M |
| Inventory | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M |
| Total current assets | $293M | $347M | $367M | $395M | $408M | $439M | $432M | $439M |
| Total assets | $434M | $489M | $601M | $625M | $632M | $656M | $645M | $651M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $153M | $162M | $135M | $138M | $121M | $118M | $104M | $109M |
| Total equity | $281M | $327M | $466M | $486M | $511M | $539M | $541M | $543M |